Viralgen exclusive technology for rAAV production

Our technology

Triple Plasmid Transfection

Genes are the blueprints of the human body. These DNA based messages provide the body’s cells with instructions on how to make proteins that are critical to its function. The appearance of faulty proteins is often caused by corrupted or missing genes, or by erroneous modifications to downstream products of genes.

Traditional pharmaceutical based treatments typically modify components of the cell or its environment to induce a therapeutic response. Gene therapy, on the other hand, is focused on utilizing viral-based technologies that deliver therapeutic genes to human cells or tissues to correct the genetic defect directly.

Harnessing viruses, otherwise known as vectors, with their naturally evolved capabilities to deliver therapeutic genetic material to living cells, is one of the most exciting advances in modern medicine, having broad future therapeutic implications for a vast array of diseases.

Historically, there were several recombinant viral vectors available to deliver therapeutic genetic cargo to the body’s cells. Recombinant adeno-associated virus (rAAV) has become the dominant gene-delivery vector of choice, aimed at curing or treating the disease by delivering new or replacement genes to code for therapeutic proteins in humans.

rAAV offers the advantages of no pathogenicity: efficient long-term gene expression, ease of genetic manipulation, and the property of low, or in many cases, absent immune response. No other gene delivery tool offers such a desirable array of properties.

Sin título-2Triple-plasmid transfectionpAAV-transgeneCotransfectionrAAVX-transgenepAAVrep2capXpHelperVA RNAPro10™cell lineE1aE1bE1bE1aE2AE4PromoterTransgeneAAV rep2AAVX cap

Flowchart cGMP Production

Your browser does not support SVGs

Pro10™ Cell line

Proprietary Pro10™ is an animal-derived component-free suspension-adapted cell line, derived from HEK293 cells. Pro10™ is a unique high yield universal system that can produce all serotypes and chimeric forms of rAAV.

Upstream process

Plasmid-based transfection of a master cell bank. 50 to 500L single-use stirred-tank bioreactors.

Downstream process

VIRALGEN has the capability of continuously processing 50L to 500L batches with depth filtration, affinity and Ion exchange chromatography & tangential flow filtration.

Fill & Finish

Inhouse aseptic fill & finish process.


Manufacturing includes drug product and in-process testing services to ensure the identity, quality and purity of the product.


VIRALGEN has been accredited as a Pharmaceutical Laboratory in July 2019 by the AEMPS (Spanish Agency for Medicines and Health Products) and has received the cGMP (Good Manufacturing Practices) certification for the manufacture of recombinant Adeno associated Viral Vectors from the AEMPS which forms part of the European Medicines Agency.